Jim Fox has extensive experience leading global technology and healthcare businesses.
He led the start up of product development company Invetech. When Invetech merged with ASX-listed Vision Systems in 1993, Jim took over as CEO of the combined entity. He held that role until January 2007, when Vision Systems, by then a global cancer diagnostics company, was successfully sold to Danaher for $816 million.
Jim is currently a non-executive director of NASDAQ-listed GenMark Diagnostics, having served as chairman of the board from 2014 until February 2020. He is also a non-executive director of TTP Group, a privately held company based in the UK. Jim has previously sat on the boards of Air New Zealand, Novasyte, and Biota Pharmaceuticals.
Jim received his Bachelor’s, Master’s and Ph.D. degrees in Engineering from the University of Melbourne.